Cardiac cath steroid prep

In the Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker (LEADLESS II) trial, a leadless pacer was implanted successfully in 504 of 523 patients. At six months, 90% of patients met the primary efficacy endpoint of acceptable pacing threshold (≤2 V at ms) and sensing amplitude (≥5mV or value greater than or equal to evaluate implantation). 93% of the patients met the primary safety endpoint of freedom from device-related serious adverse events. Device related serious events were seen in % of patients, including device dislodgment with percutaneous retrieval, cardiac perforation and pacing threshold elevation requiring retrieval and device replacement. 5

Cardiac cath steroid prep

cardiac cath steroid prep

Media:



http://buy-steroids.org